Home > Boards > US Listed > Biotechs >

Stemline Therapeutics (STML)

Add STML Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/20/2019 8:00:40 AM - Followers: 15 - Board type: Free - Posts Today: 0

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients.

In a multicenter Phase 1/2 trial in patients with advanced hematologic cancer, SL-401 demonstrated single agent activity in multiple indications, including durable complete responses (CRs) in relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and an overall survival (OS) improvement relative to historical data in the most heavily pre-treated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into a pivotal Phase 2b trial in patients with BPDCN and a registration-directed Phase 2b study in patients with advanced AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer.

Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. Stemline also possesses a landmark portfolio of intellectual property that includes the earliest filings in the CSC field covering CSC-directed therapeutics, diagnostics, and drug discovery.

Stemline Therapeutics has developed a Discovery Platform called StemScreen® to identify novel compounds that target and kill CSCs.

StemScreen®-1 is a 3-step platform which involves:

1. CSC isolation and target identification.

2. Proprietary in silico screen which identifies compound classes that interact with CSC targets.

3. Battery of anti-CSC functional assays that test compounds for activity against CSCs both in vitro and in vivo. In some cases the Company has employed medicinal chemistry to optimize lead compounds. Stemline currently has 6 active oncology programs — three of which have yielded lead compounds to date.

StemScreen®-2 is a proprietary high throughput screen currently in development. StemScreen®-2 takes advantage of a landmark discovery that cancer cell lines harbor CSCs. This technology enables the development of high throughput screens for compounds that target CSCs.

Pre-Clinical Programs

Clinical Programs

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
STML News: Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress 05/20/2019 07:00:00 AM
STML News: Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting 05/16/2019 07:00:00 AM
STML News: Quarterly Report (10-q) 05/10/2019 04:17:38 PM
STML News: Current Report Filing (8-k) 05/10/2019 07:31:17 AM
STML News: Stemline Therapeutics Reports First Quarter 2019 Financial Results 05/10/2019 06:30:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#48   Three upcoming poster presentations at EHA: http://www.globenewswire.com/news-r biotech_researcher 05/20/19 08:00:40 AM
#47   STML reports Q1 2019 results. First quarter since biotech_researcher 05/11/19 07:03:45 AM
#46   STML has never looked back through all this biotech_researcher 05/09/19 02:44:58 PM
#45   Stemline Therapeutics Announces New England Journal of Medicine biotech_researcher 04/27/19 09:08:23 AM
#44   Ripping...... biotech_researcher 04/23/19 10:11:31 PM
#43   Approved by FDA for BPDCN, rare blood cancer biotech_researcher 04/23/19 02:48:30 PM
#42   CD123 makes a great target for many indications.. biotech_researcher 03/30/19 08:38:43 AM
#41   Sold last week at $9.47 and then bought Lazarus 01/15/19 10:58:36 AM
#40   Unmet medical need. Should strengthen.... biotech_researcher 12/30/18 07:54:30 PM
#39   Now that the stock is in the toilet Lazarus 12/21/18 11:08:47 AM
#38   http://petroglobalnews24.com/2017-03-22-ladenburg-thalmann-financial-services-an cashcow3 03/23/17 08:03:14 AM
#37   Perceptive Advisors LLC bought a new position in cashcow3 03/23/17 08:02:57 AM
#36   Stemline Therapeutics Inc (NASDAQ:STML) has been given a cashcow3 03/23/17 08:01:36 AM
#35   http://www.globenewswire.com/news-release/2017/03/23/943431/0/en/Stemline-Therap cashcow3 03/23/17 08:00:53 AM
#34   HUGE NEWS cashcow3 03/23/17 08:00:36 AM
#33   Stemline Therapeutics Inc (NASDAQ:STML): What’s The Other Side trendmkr 02/03/17 09:12:24 PM
#32   Stemline says patient died during Phase 2 BPDCN trial guchu 02/03/17 09:05:51 AM
#31   Shares of Stemline Therapeutics (NASDAQ:STML) tumbled nearly 37% guchu 02/03/17 09:01:42 AM
#30   Side Effect Kills Cancer Patient in Stemline Therapeutics guchu 02/03/17 08:58:54 AM
#29   Traded a small amount here, but long term floWteiuQ 05/16/16 12:20:06 PM
#28   Would like to see this hold over 6$ Cbdpotential 04/21/16 04:12:04 PM
#27   $STML Looking good Cbdpotential 04/21/16 04:10:58 PM
#26   bot starter in stml at $6.31...gl....target $7.50 luvgrowth 12/22/15 11:35:15 AM
#25   Cut my loss stockmarkot 05/05/15 03:24:22 PM
#24   Im out! Too much pain stockmarkot 05/05/15 03:24:14 PM
#23   $STML under rader but not by analyst 5 stockmarkot 04/28/15 07:19:50 PM
#22   $STML recent news/filings stocktrademan 07/31/14 02:42:18 PM
#21   Roth Capital Reiterates Buy On Stemline Following Initiation maytepper 07/28/14 04:14:03 PM
#20   $STML $22.66 Bought a small position @ $21.39, $$$eeker 02/07/14 11:28:07 AM
#19   $STML Worth reading. http://bit.ly/MxAfUV $$$eeker 02/07/14 10:42:33 AM
#18   Check it our for yourselves: http://xml.10kwizard.com/filing_raw.php?repo=tenk&i LPC47 12/02/13 08:38:21 PM
#17   Insiders making big buys at 20$ here. Very LPC47 12/02/13 06:41:46 PM
#16   Yes. Just watch ;) LPC47 12/02/13 06:39:57 PM
#15   Still thinking 50 eoy? Jordantrae 11/30/13 10:04:08 PM
#14   Stemline Therapeutics target raised to $70 at Aegis biocqr 10/30/13 01:36:39 PM
#13   Big gap up after the political dark clouds LPC47 10/10/13 03:03:38 PM
#12   Taking a big position here. Tremendous underwriting support. LPC47 10/10/13 02:48:14 PM
#11   Jefferies initiates Stemline Therapeutics with a Buy; shares higher biocqr 08/29/13 03:40:06 PM
#10   I thought it was very bullish. ronpopeil 08/14/13 10:35:15 AM
#9   Wedbush presentation... biocqr 08/14/13 10:32:18 AM
#8   They may have a replay on their website. ronpopeil 08/14/13 10:30:53 AM
#7   They may have a replay on their website. ronpopeil 08/14/13 10:30:48 AM
#6   Oh was it? i missed that ECole 08/14/13 10:27:25 AM
#5   I thought the presentation was very bullish ronpopeil 08/14/13 10:24:22 AM
#4   Wedbush 2013 Life Sciences Management Access Conference updates ECole 08/14/13 10:17:50 AM
#3   STML presentation @ JMP Healthcare conf... biocqr 07/10/13 11:18:44 AM
#2   SL-401 receives Orphan Drug designation in BPDCN. A DonShimoda 06/18/13 05:05:38 PM
#1   Stemline's June 2013 Corporate Presentation can be files.shareholder.com/d DonShimoda 06/18/13 05:01:46 PM